Previous 10 | Next 10 |
SAN DIEGO , Sept. 30, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV) , a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, pros...
Thinly traded nano cap Trovagene (NASDAQ: TROV ) is up 14% premarket on light volume in response to its announcement that it has completed its Phase 1b clinical trial evaluating lead drug onvansertib, combined with chemo, for the treatment of acute myeloid leukemia (AML). Mor...
SAN DIEGO , Sept. 19, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, prostate ...
Editor's note: Seeking Alpha is proud to welcome GG Pharma Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » TrovaGene, I...
SAN DIEGO , Sept. 3, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal ...
TrovaGene (NASDAQ: TROV ) shareholders have filed to offer up to 1,632,479 shares, issuable on exercise of warrants. More news on: TrovaGene, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Thinly traded nano cap Trovagene (NASDAQ: TROV ) is up 1% premarket on light volume in response to positive data from its ongoing Phase 2 clinical trial evaluating onvansertib, combined with Johnson & Johnson's Zytiga (abiraterone acetate) and prednisone, in patients with...
SAN DIEGO , Aug. 26, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV) , a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including prostate, color...
TrovaGene (NASDAQ: TROV ) -22% . More news on: TrovaGene, Inc., Jumia Technologies AG, Baozun Inc., News on the U.S. economy, Read more ...
Synlogic (NASDAQ: SYBX ) -25% in reaction to its decision to terminate development of SYNB1020 for the treatment of hyperammonemia. More news on: Synlogic, Inc., Sarepta Therapeutics, Inc., Fabrinet, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today a...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga&...
SAN DIEGO , April 28, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, ...